Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Different colchicine doses versus celecoxib for gout flare prophylaxis during febuxostat initiation
ChiCTR2500101746Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Apr 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of colchicine, celecoxib and febuxostat in gout (3 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: mean number of gout flares between 0 and 6 months. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
colchicinecelecoxibfebuxostat
03
Conditions
gout
Beyond the preview
Go deeper on ChiCTR2500101746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101746.